Journal of VitreoRetinal Diseases最新文献

{"title":"Longitudinal Follow-Up of Macular Telangiectasis Type 2-Like Maculopathy in Hereditary Sensory and Autonomic Neuropathy Type 1.","authors":"Ogul E Uner, Kaiyo Shi, Ronald P Davis, Aristomenis Thanos","doi":"10.1177/24741264261496254","DOIUrl":"10.1177/24741264261496254","url":null,"abstract":"<p><strong>Purpose: </strong>To report the long-term follow-up of macular telangiectasia type 2-like disease in a patient with hereditary sensory and autonomic neuropathy 1.</p><p><strong>Methods: </strong>A single case was reviewed over 15 years.</p><p><strong>Results: </strong>A 48-year-old White woman with chronic peripheral neuropathy and fractures presented with worsening blurry vision. Best-corrected visual acuity (BCVA) was 20/70 OD and 20/25 OS. Initial examination showed bilateral subfoveal retinal cavitation and pseudovitelliform lesions, with cone dysfunction on multifocal electroretinography. Genetic testing demonstrated a serine palmitoyl transferase mutation consistent with hereditary sensory and autonomic neuropathy 1. Over 15 years, bilateral full-thickness macular holes, retinal pigmentary changes, and outer retinal veno-venous anastomoses developed. BCVA was 20/70 OU. Bilateral vitrectomy with inverted internal limiting membrane flaps improved BCVA to 20/60 OD and 20/50 OS.</p><p><strong>Conclusions: </strong>Hereditary sensory and autonomic neuropathy 1 can cause macular telangiectasia type 2-like maculopathy with atypical features but a long-term course similar to that of sporadic macular telangiectasia type 2, including macular hole formation. Genetic testing for hereditary sensory and autonomic neuropathy 1 should be considered when early peripheral neuropathy precedes macular disease.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261496254"},"PeriodicalIF":1.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative Analysis of Fibrovascular Membrane Traction in Antivascular Endothelial Growth Factor-Associated Crunch Syndrome Using Integrated Ultrawide-Field Imaging and Swept-Source Optical Coherence Tomography.","authors":"Yafeng Li, Assel Talaspayeva, Samet Gulkas, Mohamed Ashraf","doi":"10.1177/24741264261490794","DOIUrl":"10.1177/24741264261490794","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize changes in fibrovascular membrane traction following antivascular endothelial growth factor (anti-VEGF) treatment in eyes with proliferative diabetic retinopathy.</p><p><strong>Methods: </strong>Fibrovascular membrane traction was decomposed into anteroposterior, tangential, and bridging vectors and quantitatively assessed using standardized ultrawide-field fundus imaging with navigated swept-source optical coherence tomography (OCT).</p><p><strong>Results: </strong>Five eyes of 5 patients with high-risk proliferative diabetic retinopathy demonstrated progression of fibrovascular membrane traction following intravitreal anti-VEGF injection. Ultrawide-field fundus imaging with navigated swept-source OCT showed increases in anteroposterior traction ranging from 5.3% to 62% and in tangential traction ranging from 3% to 14% compared with pre-injection measurements (follow-up interval, 1-10 weeks). Over a 6-month follow-up period, fibrovascular membrane traction remained stable in 4 eyes, whereas 1 eye developed macula-threatening traction and vision loss requiring vitrectomy.</p><p><strong>Conclusions: </strong>This retrospective series demonstrates dynamic changes in fibrovascular membrane traction following anti-VEGF therapy in proliferative diabetic retinopathy. Quantitative assessment using integrated ultra-widefield imaging and navigated swept-source OCT may provide a useful approach for monitoring tractional changes and informing clinical decision-making regarding fibrovascular membrane management. Larger prospective studies are warranted to validate these findings.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261490794"},"PeriodicalIF":1.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exudative Vitreoretinopathy and Vasoproliferative Retinal Lesion in <i>CTNNB1</i> Syndrome.","authors":"Louis K Aghanwa, Aliaa Abdelhakim, Brian Marr, Gaetano R Barile","doi":"10.1177/24741264261491129","DOIUrl":"https://doi.org/10.1177/24741264261491129","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the presentation, management, and genetic diagnosis of a young adult with <i>CTNNB1</i>-associated vitreoretinopathy and a vasoproliferative retinal tumor.</p><p><strong>Methods: </strong>A single case was evaluated.</p><p><strong>Results: </strong>A 22-year-old woman presented with progressive tractional changes in the left eye due to a peripheral vasoproliferative retinal tumor and exudative retinal detachment. She underwent primary vitrectomy with membrane peeling, endolaser, cryotherapy, and intravitreal antivascular endothelial growth factor, followed by vitrectomy and scleral buckling for recurrent detachment. Additional findings included contralateral chorioretinal coloboma and high refractive error. Retinal reattachment and vasoproliferative retinal tumor involution were achieved with surgery. Fluorescein angiography revealed peripheral avascularity in the right eye and leakage from the vasoproliferative retinal tumor in the left. Exome sequencing identified a heterozygous de novo <i>CTNNB1</i> variant, consistent with <i>CTNNB1</i>-associated syndrome. This case expands the known ophthalmic phenotype to include secondary vasoproliferative retinal tumor complicating <i>CTNNB1</i>-associated vitreoretinopathy.</p><p><strong>Conclusions: </strong>Discrete vasoproliferative retinal tumor and chorioretinal coloboma represent underrecognized features of <i>CTNNB1</i>-related vitreoretinopathy. Early recognition, surgical intervention, and genetic testing are critical in young patients with atypical vitreoretinal disease.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261491129"},"PeriodicalIF":1.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Retinal Necrosis in an Infant With Corneal and Macular Scarring: Other Considerations-Commentary.","authors":"Moustafa S Magliyah, Srinivasan Sanjay","doi":"10.1177/24741264261495457","DOIUrl":"https://doi.org/10.1177/24741264261495457","url":null,"abstract":"","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261495457"},"PeriodicalIF":1.3,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal Vasoproliferative Tumors in Real-World Practice.","authors":"Piero Barrera-Arshavin, Juan Cristóbal Ormeño-Illanes, Camilo Urzúa-Álvarez, Marcelo Azócar-Barrera, Bruno Caselli-Morgado, Alfredo Rojas-Torres, Álvaro Bofill Ramírez, José Manuel López-Astaburuaga, Sergio Zacharías-Santamaría, Efraín Pérez Argandoña, Jorge Orellana-Ríos, Luis Filsecker-López, Juan Ignacio Verdaguer-Díaz","doi":"10.1177/24741264261484834","DOIUrl":"https://doi.org/10.1177/24741264261484834","url":null,"abstract":"<p><p><b>Purpose:</b> To describe the clinical, anatomic, functional, and therapeutic characteristics of patients with retinal vasoproliferative tumors in real-world clinical practice, comparing the clinical features of primary and secondary tumors. <b>Methods:</b> A multicenter, retrospective, longitudinal case series study was conducted, including cases of retinal vasoproliferative tumors at 3 ophthalmology referral centers in Chile between 2006 and 2026. A total of 24 eyes from 23 patients with a clinical diagnosis of retinal vasoproliferative tumor were included. Demographic, topographic, biometric, functional, and treatment variables were analyzed. Parametric and nonparametric tests were used. <b>Results:</b> The mean age was 45.6 ± 15.2 years; 70.8% were primary tumors, and 29.2% were secondary. Most cases were unilateral (91.7%) and active at diagnosis (79.2%), with a predominance in the inferior and inferotemporal quadrants. The mean baseline best-corrected visual acuity was 0.75 ± 0.64 logMAR, and the final best-corrected visual acuity was 0.60 ± 0.79 logMAR, with no statistically significant overall functional improvement (<i>P</i> = .27). Laser photocoagulation, the most performed treatment, was done in 54.2%. A favorable anatomic response was achieved in 91.7% of eyes. Retreatment was more frequent in secondary than in primary tumors (85.7% vs 35.3%; absolute risk difference, +50.4%; odds ratio, 11.0; 95% CI, 1.06-114.1; Fisher exact <i>P</i> = .069). <b>Conclusions:</b> Retinal vasoproliferative tumors achieved a high rate of anatomic control with currently used therapies; however, functional recovery was limited. Secondary tumors showed a clinically important but statistically imprecise trend toward greater retreatment need; this finding should be regarded as hypothesis-generating and warrants close follow-up.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261484834"},"PeriodicalIF":1.3,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13627463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Topical Bromfenac 0.09% on Pain Following Intravitreal Antivascular Endothelial Growth Factor Injections.","authors":"Kathryn Achuck, Rebecca Soares, Danielle Solish, Marko Popovic, Tina Felfeli, Rajeev Muni, Chirag Shah, Darrell Baskin, Jason Hsu, Sunir Garg","doi":"10.1177/24741264261464998","DOIUrl":"10.1177/24741264261464998","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the effect of topical bromfenac 0.09% on pain following intravitreal (IVT) injection of antivascular endothelial growth factor (anti-VEGF) medications in patients diagnosed as having choroidal neovascularization secondary to age-related macular degeneration or other etiologies, diabetic macular edema, diabetic retinopathy, or macular edema associated with retinal vein occlusion.</p><p><strong>Methods: </strong>A total of 78 adult patients scheduled to receive bilateral anti-VEGF IVT injections were randomized to receive topical bromfenac 0.09% in 1 eye and artificial tears in the fellow eye (control) immediately before the anti-VEGF treatment at 2 academic institutions from March 2021 to June 2022. Pain was evaluated using the Wong-Baker FACES Pain Rating Scale (score range, 0-10) and the Short-Form McGill Pain Questionnaire (score range, 0-5) at baseline (preinjection) and 5 minutes, 6 hours, and 24 hours following injection. Wilcoxon signed-rank sum test was used for statistical comparisons.</p><p><strong>Results: </strong>In total, 156 eyes were analyzed. Mean baseline pain scores were similar between the bromfenac 0.09% and control groups. Five minutes after injection, eyes randomized to receive bromfenac 0.09% had significantly less pain compared with control eyes receiving artificial tears, on both the Wong-Baker FACES scale (mean raw score, 2.29 vs 2.79; <i>P</i> = .0275) and the McGill Pain Questionnaire (mean raw score, 1.13 vs 2.36; <i>P</i> = .0135). No significant difference in pain scores was noted at 6 hours or 24 hours post-IVT injection.</p><p><strong>Conclusions: </strong>Bromfenac 0.09% solution administered to the study eye before IVT anti-VEGF injection reduced pain 5 minutes after injection in comparison with artificial tears. There was no difference in pain between the 2 groups at 6 hours or 24 hours post-IVT injection.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261464998"},"PeriodicalIF":1.3,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Systemic Complications of Antivascular Endothelial Growth Factor Therapies in Retinal Diseases.","authors":"Adarsh Mallepally, Michelle Lam, Esha Mittal, Raziyeh Mahmoudzadeh, Mirataollah Salabati, Jessica Randolph","doi":"10.1177/24741264261484033","DOIUrl":"10.1177/24741264261484033","url":null,"abstract":"<p><p><b>Purpose:</b> To compare the systemic safety profiles of antivascular endothelial growth factor (anti-VEGF) agents using a large real-world dataset. <b>Methods:</b> The TriNetX Research Network database was used to identify adults with macular edema secondary to diabetes, retinal vein occlusion, or age-related macular degeneration who received bevacizumab, ranibizumab, or aflibercept (2012-2022) or faricimab (2022-2024). The bevacizumab cohort was matched with the other cohorts using propensity score matching to account for demographic characteristics and comorbidities. Outcomes included stroke, venous thromboembolism, myocardial infarction, hypertension, brain hemorrhage, and renal function. <b>Results:</b> In the propensity score-matched cohorts comparing outcomes between bevacizumab and aflibercept (each n = 9538), bevacizumab was associated with higher mean blood urea nitrogen level (28.07 mg/dL vs 26.89 mg/dL; <i>P</i> = .017), higher mean serum creatinine level (1.86 mg/dL vs 1.72 mg/dL; <i>P</i> = .004), and lower mean estimated glomerular filtration rate (55.64 mL/min vs 58.01 mL/min; <i>P</i> = .003) at 1 to 6 months' follow-up. Compared with the faricimab cohort, the bevacizumab cohort (each n = 3500) showed increased risk of stroke (risk ratio [RR], 1.71, 95% CI, 1.19-2.48), venous thromboembolism (RR, 1.80, 95% CI, 1.11-2.93), myocardial infarction (RR, 1.72, 95% CI, 1.19-2.49), and hypertension (RR, 1.47, 95% CI, 1.19-1.83) within 2 years of follow-up. No significant differences were found between the bevacizumab and ranibizumab cohorts (each n = 2211). <b>Conclusions:</b> Bevacizumab may confer an increased risk of cardiovascular events and differences in renal function parameters compared with aflibercept and faricimab, but not ranibizumab. This underscores the importance of tailoring anti-VEGF therapy to patient-specific profiles, particularly in patients with underlying cardiovascular and renal comorbidities. Further studies in lower-comorbidity populations are needed to clarify these associations.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261484033"},"PeriodicalIF":1.3,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149062178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stepwise 900 µm to 1100 µm Microneedle Selection for Suprachoroidal Triamcinolone Acetonide.","authors":"Victor Bellanda, Waseem Midlij, Danny A Mammo","doi":"10.1177/24741264261469695","DOIUrl":"10.1177/24741264261469695","url":null,"abstract":"<p><strong>Purpose: </strong>To describe real-world microneedle size use during suprachoroidal triamcinolone acetonide injection and identify patient-level factors associated with 900 µm vs 1100 µm microneedle requirement.</p><p><strong>Methods: </strong>A retrospective study was performed of all eyes receiving suprachoroidal triamcinolone acetonide between November 2022 and May 2026 from a single provider at a tertiary referral center. The primary outcome was microneedle size requirement (900 µm vs 1100 µm) at the first injection. The secondary outcome was needle size transition on repeat injections among eyes initially injected with the 900 µm needle. Generalized estimating equations with patient-level clustering were used for the primary analysis. Safety outcomes were also assessed.</p><p><strong>Results: </strong>A total of 103 eyes from 88 patients were included, comprising 202 injections. Using a standardized stepwise approach of attempting the 900 µm needle at first injection in all eyes, 64 eyes (62.1%) were successfully injected, while 39 eyes (37.9%) required the 1100 µm needle. On multivariable analysis, self-identified Black race was independently associated with requirement of a 1100 µm needle (adjusted odds ratio, 8.59, 95% CI, 2.42-30.48; <i>P</i> < .001), robust across primary, multivariable, and sensitivity analyses. No other demographic or ocular variable was significantly associated with needle size. No adverse safety events were observed.</p><p><strong>Conclusions: </strong>A stepwise approach beginning with the 900 µm needle is safe and effective for most patients and may optimize suprachoroidal drug delivery across a diverse patient population. Self-identified Black race is strongly and independently associated with requirement of a 1100 µm microneedle for suprachoroidal injection, potentially reflecting ancestry-related differences in scleral and suprachoroidal anatomy.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261469695"},"PeriodicalIF":1.3,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unilateral Fibrovascular Vitreoretinal Proliferation Associated With Retinal Astrocytic Hamartoma Revealing Tuberous Sclerosis Complex in Adulthood.","authors":"Efe Polat Özkan, Gamze Taş Aygar, Pınar Çiçek Kaya, Berrak Şekeryapan Gediz","doi":"10.1177/24741264261486753","DOIUrl":"10.1177/24741264261486753","url":null,"abstract":"<p><strong>Purpose: </strong>To report an unusual presentation of previously undiagnosed tuberous sclerosis complex manifesting as unilateral fibrovascular vitreoretinal proliferation associated with retinal astrocytic hamartoma complicated by vitreous hemorrhage (VH).</p><p><strong>Methods: </strong>A single case was reviewed.</p><p><strong>Results: </strong>A 29-year-old woman presented with visual loss in the left eye and longstanding reduced vision since childhood. Examination revealed a retinal astrocytic hamartoma in the right eye and VH, fibrovascular vitreoretinal proliferation, retinal disorganization, and macular thickening in the left eye. Fluorescein angiography demonstrated telangiectatic vessels and late-phase leakage. The presence of accompanying cutaneous lesions prompted multidisciplinary evaluation, which revealed systemic tuberous sclerosis complex associated with a heterozygous <i>TSC1</i> mutation. Following a single intravitreal injection of bevacizumab, regression of the VH and stabilization of the proliferative retinal findings were observed during 1 year of follow-up.</p><p><strong>Conclusions: </strong>Retinal astrocytic hamartomas associated with tuberous sclerosis complex are generally benign and asymptomatic; however, rare progressive forms may present with fibrovascular vitreoretinal proliferative complications. Ocular manifestations may play a critical role in diagnosing previously unrecognized tuberous sclerosis complex.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261486753"},"PeriodicalIF":1.3,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13586079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Culture-Proven <i>Haemophilus influenzae</i> Endophthalmitis After Intravitreal Topotecan for Retinoblastoma.","authors":"Renu P Rajan, Muthukrishnan V, Usha Kim, Naresh B Kannan, Kim Ramasamy, Arpit Sharma","doi":"10.1177/24741264261486768","DOIUrl":"10.1177/24741264261486768","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the management and clinical outcome of severe infectious endophthalmitis after intravitreal (IVT) topotecan injection for retinoblastoma in an eye with potential vision.</p><p><strong>Methods: </strong>A single case was reviewed.</p><p><strong>Results: </strong>An 8-month-old child with bilateral retinoblastoma receiving systemic chemotherapy developed acute endophthalmitis in the only eye with potential vision 3 days after the sixth IVT topotecan injection. Urgent 23-gauge pars plana vitrectomy was performed to clear dense vitritis and maintain oncologic control using a closed-system approach, melphalan irrigation (5 µg/mL), IVT topotecan, port-site cryotherapy, and silicone oil tamponade. The patient also received IVT vancomycin, ceftazidime, and voriconazole. Vitreous culture identified <i>Haemophilus influenzae</i>. The infection resolved, the tumor continued to regress, and no extraocular tumor spread was observed during 24 months of follow-up.</p><p><strong>Conclusions: </strong>Early, tailored vitrectomy may help preserve vision in severe endophthalmitis after IVT chemotherapy for retinoblastoma when strict oncologic precautions are maintained, with long-term follow-up required to monitor for tumor recurrence or extraocular spread.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261486768"},"PeriodicalIF":1.3,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}